The Intravenous-to-Subcutaneous Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Intravenous-to-Subcutaneous Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Intravenous-to-Subcutaneous Drugs market. The report focuses on well-known providers in the global Intravenous-to-Subcutaneous Drugs industry, market segments, competition, and the macro environment.
Under COVID-19 Outbreak, how the Intravenous-to-Subcutaneous Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.
In Chapter 2.4, we analyzed industry trends in the context of COVID-19.
In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.
In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.
In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.
A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.
Key players in the global Intravenous-to-Subcutaneous Drugs market covered in Chapter 4:
Amgen
Capricor
AstraZeneca
Janssen
Grifols
Ferring
SteadyMed
Takeda
UCB
United Therapeutics
CSL Behring
GlaxoSmithKline
Baxter
Rhythm Metabolic
Octapharma
ScPharmceuticals
Roche
NeuroDerm
US Worldmeds
Britannia
In Chapter 11 and 13.3, on the basis of types, the Intravenous-to-Subcutaneous Drugs market from 2015 to 2026 is primarily split into:
Antibiotics
Antibodies
Anticoagulants
Antiemetics
Blood Factors
Diuretics
Hormones
Plasma-derived Immune Inhibitors
Recombinant Immunotherapeutics
Vasodilators
In Chapter 12 and 13.4, on the basis of applications, the Intravenous-to-Subcutaneous Drugs market from 2015 to 2026 covers:
Medical Care
Hospital
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:
North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 9 and 13)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2026
Table of Content 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Regulatory Scenario by Region/Country 1.4 Market Investment Scenario Strategic 1.5 Market Analysis by Type 1.5.1 Global Intravenous-to-Subcutaneous Drugs Market Share by Type (2020-2026) 1.5.2 Antibiotics 1.5.3 Antibodies 1.5.4 Anticoagulants 1.5.5 Antiemetics 1.5.6 Blood Factors 1.5.7 Diuretics 1.5.8 Hormones 1.5.9 Plasma-derived Immune Inhibitors 1.5.10 Recombinant Immunotherapeutics 1.5.11 Vasodilators 1.6 Market by Application 1.6.1 Global Intravenous-to-Subcutaneous Drugs Market Share by Application (2020-2026) 1.6.2 Medical Care 1.6.3 Hospital 1.7 Intravenous-to-Subcutaneous Drugs Industry Development Trends under COVID-19 Outbreak 1.7.1 Global COVID-19 Status Overview 1.7.2 Influence of COVID-19 Outbreak on Intravenous-to-Subcutaneous Drugs Industry Development 2. Global Market Growth Trends 2.1 Industry Trends 2.1.1 SWOT Analysis 2.1.2 Porter’s Five Forces Analysis 2.2 Potential Market and Growth Potential Analysis 2.3 Industry News and Policies by Regions 2.3.1 Industry News 2.3.2 Industry Policies 2.4 Industry Trends Under COVID-19 3 Value Chain of Intravenous-to-Subcutaneous Drugs Market 3.1 Value Chain Status 3.2 Intravenous-to-Subcutaneous Drugs Manufacturing Cost Structure Analysis 3.2.1 Production Process Analysis 3.2.2 Manufacturing Cost Structure of Intravenous-to-Subcutaneous Drugs 3.2.3 Labor Cost of Intravenous-to-Subcutaneous Drugs 3.2.3.1 Labor Cost of Intravenous-to-Subcutaneous Drugs Under COVID-19 3.3 Sales and Marketing Model Analysis 3.4 Downstream Major Customer Analysis (by Region) 3.5 Value Chain Status Under COVID-19 4 Players Profiles 4.1 Amgen 4.1.1 Amgen Basic Information 4.1.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.1.3 Amgen Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.1.4 Amgen Business Overview 4.2 Capricor 4.2.1 Capricor Basic Information 4.2.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.2.3 Capricor Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.2.4 Capricor Business Overview 4.3 AstraZeneca 4.3.1 AstraZeneca Basic Information 4.3.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.3.3 AstraZeneca Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.3.4 AstraZeneca Business Overview 4.4 Janssen 4.4.1 Janssen Basic Information 4.4.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.4.3 Janssen Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.4.4 Janssen Business Overview 4.5 Grifols 4.5.1 Grifols Basic Information 4.5.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.5.3 Grifols Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.5.4 Grifols Business Overview 4.6 Ferring 4.6.1 Ferring Basic Information 4.6.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.6.3 Ferring Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.6.4 Ferring Business Overview 4.7 SteadyMed 4.7.1 SteadyMed Basic Information 4.7.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.7.3 SteadyMed Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.7.4 SteadyMed Business Overview 4.8 Takeda 4.8.1 Takeda Basic Information 4.8.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.8.3 Takeda Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.8.4 Takeda Business Overview 4.9 UCB 4.9.1 UCB Basic Information 4.9.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.9.3 UCB Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.9.4 UCB Business Overview 4.10 United Therapeutics 4.10.1 United Therapeutics Basic Information 4.10.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.10.3 United Therapeutics Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.10.4 United Therapeutics Business Overview 4.11 CSL Behring 4.11.1 CSL Behring Basic Information 4.11.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.11.3 CSL Behring Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.11.4 CSL Behring Business Overview 4.12 GlaxoSmithKline 4.12.1 GlaxoSmithKline Basic Information 4.12.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.12.3 GlaxoSmithKline Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.12.4 GlaxoSmithKline Business Overview 4.13 Baxter 4.13.1 Baxter Basic Information 4.13.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.13.3 Baxter Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.13.4 Baxter Business Overview 4.14 Rhythm Metabolic 4.14.1 Rhythm Metabolic Basic Information 4.14.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.14.3 Rhythm Metabolic Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.14.4 Rhythm Metabolic Business Overview 4.15 Octapharma 4.15.1 Octapharma Basic Information 4.15.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.15.3 Octapharma Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.15.4 Octapharma Business Overview 4.16 ScPharmceuticals 4.16.1 ScPharmceuticals Basic Information 4.16.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.16.3 ScPharmceuticals Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.16.4 ScPharmceuticals Business Overview 4.17 Roche 4.17.1 Roche Basic Information 4.17.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.17.3 Roche Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.17.4 Roche Business Overview 4.18 NeuroDerm 4.18.1 NeuroDerm Basic Information 4.18.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.18.3 NeuroDerm Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.18.4 NeuroDerm Business Overview 4.19 US Worldmeds 4.19.1 US Worldmeds Basic Information 4.19.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.19.3 US Worldmeds Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.19.4 US Worldmeds Business Overview 4.20 Britannia 4.20.1 Britannia Basic Information 4.20.2 Intravenous-to-Subcutaneous Drugs Product Profiles, Application and Specification 4.20.3 Britannia Intravenous-to-Subcutaneous Drugs Market Performance (2015-2020) 4.20.4 Britannia Business Overview 5 Global Intravenous-to-Subcutaneous Drugs Market Analysis by Regions 5.1 Global Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Regions 5.1.1 Global Intravenous-to-Subcutaneous Drugs Sales by Regions (2015-2020) 5.1.2 Global Intravenous-to-Subcutaneous Drugs Revenue by Regions (2015-2020) 5.2 North America Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 5.3 Europe Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 5.4 Asia-Pacific Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 5.5 Middle East and Africa Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 5.6 South America Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 6 North America Intravenous-to-Subcutaneous Drugs Market Analysis by Countries 6.1 North America Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Countries 6.1.1 North America Intravenous-to-Subcutaneous Drugs Sales by Countries (2015-2020) 6.1.2 North America Intravenous-to-Subcutaneous Drugs Revenue by Countries (2015-2020) 6.1.3 North America Intravenous-to-Subcutaneous Drugs Market Under COVID-19 6.2 United States Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 6.2.1 United States Intravenous-to-Subcutaneous Drugs Market Under COVID-19 6.3 Canada Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 6.4 Mexico Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7 Europe Intravenous-to-Subcutaneous Drugs Market Analysis by Countries 7.1 Europe Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Countries 7.1.1 Europe Intravenous-to-Subcutaneous Drugs Sales by Countries (2015-2020) 7.1.2 Europe Intravenous-to-Subcutaneous Drugs Revenue by Countries (2015-2020) 7.1.3 Europe Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.2 Germany Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.2.1 Germany Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.3 UK Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.3.1 UK Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.4 France Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.4.1 France Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.5 Italy Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.5.1 Italy Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.6 Spain Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.6.1 Spain Intravenous-to-Subcutaneous Drugs Market Under COVID-19 7.7 Russia Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 7.7.1 Russia Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8 Asia-Pacific Intravenous-to-Subcutaneous Drugs Market Analysis by Countries 8.1 Asia-Pacific Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Countries 8.1.1 Asia-Pacific Intravenous-to-Subcutaneous Drugs Sales by Countries (2015-2020) 8.1.2 Asia-Pacific Intravenous-to-Subcutaneous Drugs Revenue by Countries (2015-2020) 8.1.3 Asia-Pacific Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8.2 China Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.2.1 China Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8.3 Japan Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.3.1 Japan Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8.4 South Korea Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.4.1 South Korea Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8.5 Australia Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.6 India Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.6.1 India Intravenous-to-Subcutaneous Drugs Market Under COVID-19 8.7 Southeast Asia Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 8.7.1 Southeast Asia Intravenous-to-Subcutaneous Drugs Market Under COVID-19 9 Middle East and Africa Intravenous-to-Subcutaneous Drugs Market Analysis by Countries 9.1 Middle East and Africa Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Countries 9.1.1 Middle East and Africa Intravenous-to-Subcutaneous Drugs Sales by Countries (2015-2020) 9.1.2 Middle East and Africa Intravenous-to-Subcutaneous Drugs Revenue by Countries (2015-2020) 9.1.3 Middle East and Africa Intravenous-to-Subcutaneous Drugs Market Under COVID-19 9.2 Saudi Arabia Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 9.3 UAE Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 9.4 Egypt Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 9.5 Nigeria Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 9.6 South Africa Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 10 South America Intravenous-to-Subcutaneous Drugs Market Analysis by Countries 10.1 South America Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Countries 10.1.1 South America Intravenous-to-Subcutaneous Drugs Sales by Countries (2015-2020) 10.1.2 South America Intravenous-to-Subcutaneous Drugs Revenue by Countries (2015-2020) 10.1.3 South America Intravenous-to-Subcutaneous Drugs Market Under COVID-19 10.2 Brazil Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 10.2.1 Brazil Intravenous-to-Subcutaneous Drugs Market Under COVID-19 10.3 Argentina Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 10.4 Columbia Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 10.5 Chile Intravenous-to-Subcutaneous Drugs Sales and Growth Rate (2015-2020) 11 Global Intravenous-to-Subcutaneous Drugs Market Segment by Types 11.1 Global Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Types (2015-2020) 11.1.1 Global Intravenous-to-Subcutaneous Drugs Sales and Market Share by Types (2015-2020) 11.1.2 Global Intravenous-to-Subcutaneous Drugs Revenue and Market Share by Types (2015-2020) 11.2 Antibiotics Sales and Price (2015-2020) 11.3 Antibodies Sales and Price (2015-2020) 11.4 Anticoagulants Sales and Price (2015-2020) 11.5 Antiemetics Sales and Price (2015-2020) 11.6 Blood Factors Sales and Price (2015-2020) 11.7 Diuretics Sales and Price (2015-2020) 11.8 Hormones Sales and Price (2015-2020) 11.9 Plasma-derived Immune Inhibitors Sales and Price (2015-2020) 11.10 Recombinant Immunotherapeutics Sales and Price (2015-2020) 11.11 Vasodilators Sales and Price (2015-2020) 12 Global Intravenous-to-Subcutaneous Drugs Market Segment by Applications 12.1 Global Intravenous-to-Subcutaneous Drugs Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Intravenous-to-Subcutaneous Drugs Sales and Market Share by Applications (2015-2020) 12.1.2 Global Intravenous-to-Subcutaneous Drugs Revenue and Market Share by Applications (2015-2020) 12.2 Medical Care Sales, Revenue and Growth Rate (2015-2020) 12.3 Hospital Sales, Revenue and Growth Rate (2015-2020) 13 Intravenous-to-Subcutaneous Drugs Market Forecast by Regions (2020-2026) 13.1 Global Intravenous-to-Subcutaneous Drugs Sales, Revenue and Growth Rate (2020-2026) 13.2 Intravenous-to-Subcutaneous Drugs Market Forecast by Regions (2020-2026) 13.2.1 North America Intravenous-to-Subcutaneous Drugs Market Forecast (2020-2026) 13.2.2 Europe Intravenous-to-Subcutaneous Drugs Market Forecast (2020-2026) 13.2.3 Asia-Pacific Intravenous-to-Subcutaneous Drugs Market Forecast (2020-2026) 13.2.4 Middle East and Africa Intravenous-to-Subcutaneous Drugs Market Forecast (2020-2026) 13.2.5 South America Intravenous-to-Subcutaneous Drugs Market Forecast (2020-2026) 13.3 Intravenous-to-Subcutaneous Drugs Market Forecast by Types (2020-2026) 13.4 Intravenous-to-Subcutaneous Drugs Market Forecast by Applications (2020-2026) 13.5 Intravenous-to-Subcutaneous Drugs Market Forecast Under COVID-19 14 Appendix 14.1 Methodology 14.2 Research Data Source
Intravenous-to-Subcutaneous Drugs Market
Intravenous-to-Subcutaneous Drugs Market
×